Standout Papers

Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy 2021 2026 2022 2024160
  1. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy (2021)
    Jerry R. Mendell, Samiah Al-Zaidy et al. JAMA Neurology

Immediate Impact

2 from Science/Nature 48 standout
Sub-graph 1 of 17

Citing Papers

Targeting Cytokine-Mediated Inflammation in Brain Disorders: Developing New Treatment Strategies
2025 Standout
Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics
2025 Standout
2 intermediate papers

Works of A. de Kleyn being referenced

Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy
2021 Standout
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy
2020

Author Peers

Author Last Decade Papers Cites
A. de Kleyn 227 267 140 171 5 421
Markus McColly 236 262 158 85 11 391
Emily Moorefield 74 200 139 52 8 387
Thierry Bru 89 302 83 72 7 416
Yoko Obara 99 257 37 214 6 391
Natalia Mendoza-Ferreira 309 332 146 52 8 423
Sylvain Paisant 68 414 90 113 12 472
Sylvia Vetrone 72 342 66 41 6 430
Guido Middeler 40 327 161 91 5 413
Shihoko Sata 45 223 99 68 7 380
Joscha Griger 57 358 115 104 7 483

All Works

Loading papers...

Rankless by CCL
2026